comparemela.com

Latest Breaking News On - அண்டர்ஸ் பார்மா இன்க் - Page 4 : comparemela.com

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

Published: May 06, 2021 EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc.. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various positions of increasing responsibility at Novo Nordisk including Marketing Brand Director, Women’s Health Care and leading the commercial operations and effectiveness function responsible for a 150-person sa

Antares Pharma Appoints Joseph Renda as Senior Vice

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial May 06, 2021 07:15 ET | Source: Antares Pharma, Inc. Antares Pharma, Inc. Ewing, New Jersey, UNITED STATES EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various p

Outlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities

Share this article Share this article ResearchAndMarkets.com s offering. This report titled needle free diabetes management market studies various device types such as treatment devices, diagnostic devices and artificial pancreas that respectively sub-segmented. According to the International Diabetes Federation, in 2015 one in 11 adult has diabetes and by 2040 it is expected that one in 10 adults will have diabetes. The data suggests that in 2015 every 6 seconds one person dies from diabetes. Thus, diabetes management is one of the most crucial parts to prevent life threatening effects of this disease. The ongoing research and development activities in field of diagnosis and treatment of diabetes are expected to change the aspect of market in coming years.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.